ProCE Banner Activity

Unpacking the Potential of HER3-Targeted Therapy in NSCLC

Podcast Episodes

In this podcast, Helena Yu, MD, and Rebecca S. Heist, MD, MPH, discuss ongoing clinical trials of HER3-targeted therapy for patients with advanced NSCLC and how these agents have the potential to change treatment options in this setting. 

Released: December 26, 2023

Share

Faculty

Rebecca S. Heist

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Helena Yu

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Rebecca S. Heist, MD, MPH: consultant/advisor: AbbVie, AstraZeneca, Claim Therapeutics, Daiichi Sankyo, EMD Serono, Lilly, Novartis, Regeneron, Sanofi; researcher (paid to institution): AbbVie, Agios, Corvus, Daiichi Sankyo, Erasca, Lilly, Mirati, Novartis, Turning Point. 

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Helena Yu, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Black Diamond, Daiichi Sankyo, Janssen, Taiho, Takeda; researcher: AstraZeneca, Black Diamond, Daiichi Sankyo, Cullinan, Erasca, Janssen, Novartis, Pfizer.